Daun02

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H406792

CAS#: 290304-24-4

Description: Daun02 is a Cell viability inhibitor and DNA synthisis inhibitor with IC50 values of 1.5 μM, 3.5 μM and 0.5 μM, respectively. Daun02 is also a anthracycline prodrug. Daun02 is a good substrate for beta-gal. Daun02 may be useful as a prodrug-activating enzyme in suicide gene therapy and has the potential to increase the selective toxicity of conventional antitumor agents.


Chemical Structure

img
Daun02
CAS# 290304-24-4

Theoretical Analysis

Hodoodo Cat#: H406792
Name: Daun02
CAS#: 290304-24-4
Chemical Formula: C41H44N2O20
Exact Mass: 884.25
Molecular Weight: 884.797
Elemental Analysis: C, 55.66; H, 5.01; N, 3.17; O, 36.16

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Daun02; Daun-02; Daun 02.

IUPAC/Chemical Name: 3-nitro-4-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)benzyl ((2S,3S,4S,6R)-6-((3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl)oxy)-3-hydroxy-2-methyltetrahydro-2H-pyran-4-yl)carbamate

InChi Key: BOIXMGNMIWJAEW-SGVPLSEHSA-N

InChi Code: InChI=1S/C41H44N2O20/c1-15-31(46)20(42-40(54)59-14-17-7-8-22(21(9-17)43(56)57)62-39-38(53)37(52)34(49)25(13-44)63-39)10-26(60-15)61-24-12-41(55,16(2)45)11-19-28(24)36(51)30-29(33(19)48)32(47)18-5-4-6-23(58-3)27(18)35(30)50/h4-9,15,20,24-26,31,34,37-39,44,46,48-49,51-53,55H,10-14H2,1-3H3,(H,42,54)/t15-,20-,24?,25+,26-,31+,34-,37-,38+,39+,41?/m0/s1

SMILES Code: O=C(OCC1=CC=C(O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)C([N+]([O-])=O)=C1)N[C@@H]3[C@H](O)[C@H](C)O[C@@H](OC4CC(O)(C(C)=O)CC5=C(O)C6=C(C(C7=C(OC)C=CC=C7C6=O)=O)C(O)=C45)C3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Suicide gene therapy offers the potential to increase the selective toxicity of antitumor agents by intratumoral expression of exogenous enzymes that convert nontoxic prodrugs to toxic products.

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 884.80 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Koya E, Margetts-Smith G, Hope BT. Daun02 Inactivation of Behaviorally Activated Fos-Expressing Neuronal Ensembles. Curr Protoc Neurosci. 2016 Jul 1;76:8.36.1-8.36.17. doi: 10.1002/cpns.2. PubMed PMID: 27367964.

2: Warren BL, Mendoza MP, Cruz FC, Leao RM, Caprioli D, Rubio FJ, Whitaker LR, McPherson KB, Bossert JM, Shaham Y, Hope BT. Distinct Fos-Expressing Neuronal Ensembles in the Ventromedial Prefrontal Cortex Mediate Food Reward and Extinction Memories. J Neurosci. 2016 Jun 22;36(25):6691-703. doi: 10.1523/JNEUROSCI.0140-16.2016. PubMed PMID: 27335401.

3: Pfarr S, Meinhardt MW, Klee ML, Hansson AC, Vengeliene V, Schönig K, Bartsch D, Hope BT, Spanagel R, Sommer WH. Losing Control: Excessive Alcohol Seeking after Selective Inactivation of Cue-Responsive Neurons in the Infralimbic Cortex. J Neurosci. 2015 Jul 29;35(30):10750-61. doi: 10.1523/JNEUROSCI.0684-15.2015. PubMed PMID: 26224858.

4: Cruz FC, Javier Rubio F, Hope BT. Using c-fos to study neuronal ensembles in corticostriatal circuitry of addiction. Brain Res. 2015 Dec 2;1628(Pt A):157-73. doi: 10.1016/j.brainres.2014.11.005. Epub 2014 Nov 11. PubMed PMID: 25446457; PubMed Central PMCID: PMC4427550.

5: Bastide MF, de la Crompe B, Doudnikoff E, Fernagut PO, Gross CE, Mallet N, Boraud T, Bézard E. Inhibiting Lateral Habenula Improves L-DOPA-Induced Dyskinesia. Biol Psychiatry. 2016 Mar 1;79(5):345-53. doi: 10.1016/j.biopsych.2014.08.022. Epub 2014 Sep 9. PubMed PMID: 25442003.

6: Engeln M, Bastide MF, Toulmé E, Dehay B, Bourdenx M, Doudnikoff E, Li Q, Gross CE, Boué-Grabot E, Pisani A, Bezard E, Fernagut PO. Selective Inactivation of Striatal FosB/ΔFosB-Expressing Neurons Alleviates L-DOPA-Induced Dyskinesia. Biol Psychiatry. 2016 Mar 1;79(5):354-61. doi: 10.1016/j.biopsych.2014.07.007. Epub 2014 Jul 15. PubMed PMID: 25146322.

7: Cruz FC, Babin KR, Leao RM, Goldart EM, Bossert JM, Shaham Y, Hope BT. Role of nucleus accumbens shell neuronal ensembles in context-induced reinstatement of cocaine-seeking. J Neurosci. 2014 May 28;34(22):7437-46. doi: 10.1523/JNEUROSCI.0238-14.2014. PubMed PMID: 24872549; PubMed Central PMCID: PMC4035511.

8: Cruz FC, Koya E, Guez-Barber DH, Bossert JM, Lupica CR, Shaham Y, Hope BT. New technologies for examining the role of neuronal ensembles in drug addiction and fear. Nat Rev Neurosci. 2013 Nov;14(11):743-54. doi: 10.1038/nrn3597. Epub 2013 Oct 3. Review. PubMed PMID: 24088811; PubMed Central PMCID: PMC4530016.

9: Fanous S, Goldart EM, Theberge FR, Bossert JM, Shaham Y, Hope BT. Role of orbitofrontal cortex neuronal ensembles in the expression of incubation of heroin craving. J Neurosci. 2012 Aug 22;32(34):11600-9. doi: 10.1523/JNEUROSCI.1914-12.2012. PubMed PMID: 22915104; PubMed Central PMCID: PMC3435881.

10: Koya E, Golden SA, Harvey BK, Guez-Barber DH, Berkow A, Simmons DE, Bossert JM, Nair SG, Uejima JL, Marin MT, Mitchell TB, Farquhar D, Ghosh SC, Mattson BJ, Hope BT. Targeted disruption of cocaine-activated nucleus accumbens neurons prevents context-specific sensitization. Nat Neurosci. 2009 Aug;12(8):1069-73. doi: 10.1038/nn.2364. Epub 2009 Jul 20. PubMed PMID: 19620976; PubMed Central PMCID: PMC2752202.

11: Farquhar D, Pan BF, Sakurai M, Ghosh A, Mullen CA, Nelson JA. Suicide gene therapy using E. coli beta-galactosidase. Cancer Chemother Pharmacol. 2002 Jul;50(1):65-70. Epub 2002 Jun 8. PubMed PMID: 12111114.